Theravance has initiated a dose-ranging Phase 2b study of its TD-4208 long-acting muscarinic antagonist (LAMA), the company announced. The study will compare four different dosages of TD-4208 and placebo, all delivered once daily via jet nebulizer, in about 350 patients with moderate to severe COPD over a 28-day period.
According to the company, “The goal of Theravance’s LAMA program is to develop a once-daily inhaled medicine in a nebulizer for the treatment of a subset of COPD patients who are underserved by current hand held products or prefer nebulized therapy.”
Theravance Senior VP of Research and Development Mathai Mammen said, “We are very pleased with the progression of TD-4208 into a Phase 2b study in patients with COPD. We believe we have a significant opportunity to meet the needs of certain patients who may need or prefer nebulized therapy.”
Read the Theravance press release.
